Stock research
ALZN Alzamend Neuro Inc
Healthcare • Biotechnology
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a...…
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
1Y change
-41.81%
Range high
$2.62
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in ALZN?
Price
Showing 1Y history. Source: FMP historical price full.
- Prev Close
- $1.45
- Day High
- $1.43
- Day Low
- $1.38
- 52w High
- $2.68
- 52w Low
- $0.84
- Volume
- 897
- Avg Volume
- Beta
- 0.193
* TTM/most recent where available
Company
- Ticker
- ALZN
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Stephan Jackman
- Employees
- 7
- Website
- www.alzamend.com
Key Metrics
- Market Cap
- 5.44M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).